Major study tracks cancer and infection risks in lupus treatment
NCT ID NCT07000110
Summary
This study is monitoring the safety of the lupus medication anifrolumab by comparing patients who take it against similar patients who receive standard treatments. Researchers will track whether patients develop serious infections or cancers over time. The study is observational, meaning patients receive their normal medical care while researchers collect health data.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGCopenhagen, 23000, Denmark
-
Research Site
RECRUITINGCharenton-le-Pont, 94220, France
-
Research Site
RECRUITINGEssen, 45128, Germany
-
Research Site
RECRUITINGBarcelona, 08007, Spain
Conditions
Explore the condition pages connected to this study.